Successful Treatment of Disseminated Granuloma Annulare with Upadacitinib.

De Greef, Axel;Benjelloun, Ghita;Harkemanne, Evelyne;Baeck, Marie
(2024) Dermatology and Therapy — Vol. 14, n° 3, p. 813-817 (2024)

Files

13555_2024_Article_1117.pdf
  • Open Access
  • Adobe PDF
  • 657.42 KB

Details

Authors
  • Co-first author
  • Benjelloun, GhitaUCLouvain
    Co-first author
  • Harkemanne, Evelyneorcid-logoUCLouvain
    Author
  • Baeck, Marieorcid-logoUCLouvain
    Author
Abstract
Disseminated granuloma annulare (DGA) is an inflammatory skin disorder characterized by more than 10 erythematous, raised, ring-shaped plaques. Its treatment remains challenging, with conventional therapies showing variable efficacy. We report the case of a woman in her 50s with a 2-year history of DGA refractory to multiple treatments. Given the recent evidence of the role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in the granuloma annulare pathophysiology, treatment with upadacitinib 30 mg per day was started with rapid effectiveness and good tolerance. This case underscores the potential of JAK inhibitors as promising therapeutic options for recalcitrant granuloma annulare.
Affiliations

Citations

De Greef, A., Benjelloun, G., Harkemanne, E., & Baeck, M. (2024). Successful Treatment of Disseminated Granuloma Annulare with Upadacitinib. Dermatology and Therapy, 14(3), 813-817. https://doi.org/10.1007/s13555-024-01117-z (Original work published 2024)